William John Sempolinski Purchases New Position in GRAIL, Inc. $GRAL

William John Sempolinski purchased a new stake in GRAIL, Inc. (NASDAQ:GRAL) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 7,150 shares of the company’s stock, valued at approximately $488,000.

Several other large investors also recently added to or reduced their stakes in GRAL. Concurrent Investment Advisors LLC raised its position in GRAIL by 65.8% during the second quarter. Concurrent Investment Advisors LLC now owns 30,253 shares of the company’s stock valued at $2,065,000 after purchasing an additional 12,002 shares during the period. Nykredit A S purchased a new position in shares of GRAIL in the 2nd quarter worth approximately $96,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of GRAIL by 16.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,077 shares of the company’s stock valued at $4,511,000 after purchasing an additional 9,094 shares during the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of GRAIL during the 2nd quarter valued at approximately $96,000. Finally, Corient Private Wealth LP purchased a new stake in GRAIL during the 2nd quarter valued at $543,000.

Insider Activity

In related news, CFO Aaron Freidin sold 7,900 shares of GRAIL stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $85.01, for a total transaction of $671,579.00. Following the completion of the sale, the chief financial officer owned 253,083 shares in the company, valued at $21,514,585.83. This trade represents a 3.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Joshua Ofman sold 5,000 shares of the business’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $85.02, for a total transaction of $425,100.00. Following the completion of the sale, the chief executive officer directly owned 397,271 shares of the company’s stock, valued at approximately $33,775,980.42. This trade represents a 1.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Wall Street Zen lowered shares of GRAIL from a “hold” rating to a “sell” rating in a research note on Saturday. Wolfe Research assumed coverage on shares of GRAIL in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. TD Cowen restated a “buy” rating on shares of GRAIL in a report on Wednesday, July 15th. Mizuho upped their price target on shares of GRAIL from $58.00 to $65.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Finally, The Goldman Sachs Group initiated coverage on shares of GRAIL in a report on Friday, June 5th. They set a “neutral” rating and a $60.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $67.78.

GRAIL Stock Down 0.3%

Shares of GRAIL stock opened at $80.34 on Friday. The stock’s fifty day moving average is $72.54 and its two-hundred day moving average is $62.97. GRAIL, Inc. has a 52 week low of $33.61 and a 52 week high of $118.84. The company has a market capitalization of $3.59 billion, a PE ratio of -8.24 and a beta of 3.25.

GRAIL (NASDAQ:GRAL) last released its earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, topping the consensus estimate of ($2.66) by $0.10. The business had revenue of $44.69 million during the quarter, compared to the consensus estimate of $42.39 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. As a group, research analysts anticipate that GRAIL, Inc. will post -10.41 earnings per share for the current year.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.